A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

101

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

July 18, 2024

Study Completion Date

June 21, 2025

Conditions

Chronic Hepatitis Delta Virus Infection

Interventions

BIOLOGICAL

HH-003(20mg/kg)

20 mg/kg Q2W intravenously for 48 weeks

BIOLOGICAL

HH-003(10mg/kg)

10 mg/kg Q2W intravenously for 48 weeks

DRUG

TAF

TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Trial Locations (1)

Beijing Ditan Hospital Captial Medical University, Beijing